Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes
暂无分享,去创建一个
L Junck | R A Koeppe | S Gilman | X Wang | R. Chervin | S. Gilman | R. Koeppe | L. Junck | B. Nan | C-N Wang | X. Wang | F. Consens | A. Bhaumik | R D Chervin | B Nan | C-N Wang | F Consens | A Bhaumik | Chia-Ning Wang | Sid Gilman | Robert A. Koeppe | Ronald D. Chervin | Larry Junck | Xuejing Wang
[1] R. Mayeux,et al. Perceptual motor dysfunction in Parkinson's disease: a deficit in sequential and predictive voluntary movement. , 1983, Journal of neurology, neurosurgery, and psychiatry.
[2] N. Bohnen,et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. , 2003, Archives of neurology.
[3] C D Marsden,et al. Altered Muscarinic and Nicotinic Receptor Densities in Cortical and Subcortical Brain Regions in Parkinson's Disease , 1993, Journal of neurochemistry.
[4] S. Mirra,et al. The nucleus basalis of Meynert in neurological disease: A quantitative morphological study , 1985, Annals of neurology.
[5] M. Hallett,et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.
[6] Bernard Pillon,et al. Cognitive deficits in Parkinson’s disease , 1996, Journal of Neurology.
[7] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[8] P. Davies,et al. SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.
[9] S. Gilman,et al. Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.
[10] Sid Gilman,et al. Second consensus statement on the diagnosis of multiple system atrophy , 2008 .
[11] A. Lees,et al. Cognitive deficits in the early stages of Parkinson's disease. , 1983, Brain : a journal of neurology.
[12] Nicola J. Ray,et al. Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus , 2009, Movement disorders : official journal of the Movement Disorder Society.
[13] I. Nakano,et al. Parhnson’s Disease: Neuron Loss in the Nucleus Basah Without Concomitant Alzheimer’s Disease , 2004 .
[14] E. Perry,et al. Pathological changes in the nucleus of meynert in Alzheimer's and Parkinson's diseases , 1983, Journal of the Neurological Sciences.
[15] Jan Voogd,et al. Chapter 5 Cholinergic innervation and receptors in the cerebellum , 1997 .
[16] S. Tanada,et al. PET study of brain acetylcholinesterase in cerebellar degenerative disorders , 2008, Movement disorders : official journal of the Movement Disorder Society.
[17] V. Bigl,et al. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease , 2004, Acta Neuropathologica.
[18] C. Bouras,et al. The basal nucleus of Meynert in idiopathic Parkinson's disease , 1984, Acta neurologica Scandinavica.
[19] R. Koeppe,et al. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] D. Kuhl,et al. Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity. , 1998, Nuclear medicine and biology.
[21] Masanori Ichise,et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease , 2006, Annals of neurology.
[22] E. Sullivan,et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. , 1991, Brain : a journal of neurology.
[23] K. Fukushi,et al. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo. , 1994, Nuclear medicine and biology.
[24] K. Marder,et al. Neuropsychological characteristics of preclinical dementia in Parkinson's disease , 1995, Neurology.
[25] D Jaarsma,et al. Cholinergic innervation and receptors in the cerebellum. , 1997, Progress in brain research.
[26] M. Mintun,et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] J. Parisi,et al. Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy , 2008, Neurology.
[28] D. Kuhl,et al. In vivo studies of acetylcholinesterase activity using a labeled substrate, N‐[11C]methylpiperdin‐4‐yl propionate ([11C]PMP) , 1996, Synapse.
[29] S. Minoshima,et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease , 1996, Annals of neurology.
[30] David E. Kuhl,et al. Kinetic Modeling of N-[11C]Methylpiperidin-4-yl Propionate: Alternatives for Analysis of an Irreversible Positron Emission Tomography Tracer for Measurement of Acetylcholinesterase Activity in Human Brain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] A. Tröster,et al. Neuropsychological impairment in Parkinson's disease with and without depression. , 1995, Archives of neurology.
[32] P. Winn. How best to consider the structure and function of the pedunculopontine tegmental nucleus: Evidence from animal studies , 2006, Journal of the Neurological Sciences.
[33] N. Bohnen,et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia , 2006, Journal of Neurology.
[34] D L Price,et al. Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.
[35] M. Iyo,et al. Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] C. Marsden,et al. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. , 1988, Brain : a journal of neurology.
[37] S Tanada,et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy , 1999, Annals of neurology.
[38] D L Price,et al. Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.
[39] D E Kuhl,et al. Quantification of Muscarinic Cholinergic Receptors with [11C]NMPB and Positron Emission Tomography: Method Development and Differentiation of Tracer Delivery from Receptor Binding , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[40] S. Minoshima,et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease , 1999, Neurology.
[41] M W Mahowald,et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. , 2007, Brain : a journal of neurology.